Evidence map›Paper›PMID 41404536›Full record

ArticleCurrent treatment options in neurology2025

Update on the Treatment of Autonomic Disorders.

Abdulmunaim M Eid, Gabriel E Vázquez-Vélez, Beatriz Maliszewski, Michael Butler, Robert C Bucelli, Joel S Perlmutter, Daniel G Di Luca

Abstract read
In one paragraph

Article in Current treatment options in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdulmunaim M EidDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.
Gabriel E Vázquez-VélezDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.
Beatriz MaliszewskiDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.
Michael ButlerDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.
Robert C BucelliDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.
Joel S PerlmutterDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.
Daniel G Di LucaDepartment of Neurology, Washington University, School of Medicine, 660 S. Euclid Ave, St. Louis, MO, USA.

Funding

Training OPportunities in Translational Imaging Education and Research (TOP-TIER)T32EB021955 · NIBIB · WASHINGTON UNIVERSITY · PI Hongyu An, Joseph Edward Ippolito · 2017 to 2026
$2.4M
NIBIB NIH HHS T32 EB021955
6 · The paper itself

Abstract

Purposeof Review: Autonomic disorders disrupt homeostasis and cause symptoms such as orthostatic hypotension, urinary urgency, bladder overfilling, sexual dysfunction, constipation, and gastroparesis. Pathophysiologic mechanisms include neurodegeneration, autoimmunity, toxic exposure, medication-induced, and an array of others. Despite the lack of disease-modifying treatments for the most common etiologies, there is a plethora of therapeutic options available to treat the manifestations of dysautonomia. Here we review established and recent therapeutic strategies available for dysautonomia. We also provide a general schema to approach the management of this class of disorders in the clinical setting. Recent Findings: New emerging neuromodulatory devices are showing promise in treating dysautonomic orthostatic hypotension (spinal cord stimulators), urinary dysfunction (tibial and sacral nerve stimulators), sexual dysfunction (percutaneous perineal and sacral nerve stimulation), constipation (sacral anterior root stimulation), and gastroparesis (gastric electrical stimulation). However, most of these approaches are either experimental or not yet widely implemented. Recent medications are often more effective and/or better tolerated than older ones. These include droxidopa for orthostatic hypotension, β-3-adrenergic agonists for spastic bladder, and prucalopride, elobixibat and linaclotide for constipation. Summary: Autonomic disorders manifest with symptoms of homeostatic dysfunction. A wide variety of central and peripheral nervous system disorders cause dysautonomia. While the treatment of each specific disorder varies based on etiology, strategies overlap to manage dysautonomia. Treatments are divided into non-pharmacological, pharmacological, and neuromodulatory strategies. Here, we focus on the most common issues encountered in clinical practice and propose a stepwise approach to manage common symptoms that frequently integrates all three strategies.

Indexed as

Autonomic disordersDysautonomiaNeuromodulationOrthostatic hypotension

Identifiers

PMID41404536
PMCPMC12705040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.